Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis

14 Apr 2017

Abstract excerpt

// Franco Conforti 1,2,* , Elizabeth R. Davies 1,2,* , Claire J. Calderwood 1 , Thomas H. Thatcher 3 , Mark G. Jones 1,2 , David E. Smart 1,2 , Sumeet Mahajan 4 , Aiman Alzetani 5 , Tom Havelock 2,5 , Toby M. Maher 6,7 , Philip L. Molyneaux 6,7 , Andrew J. Thorley 7 , Teresa D. Tetley 7 , Jane A. Warner 1,2,4 , Graham Packham 8 , A. Ganesan 9 , Paul J. Skipp 4 , Benjamin J. Marshall 5 , Luca Richeldi 1,2,5 ,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28467787
DOI: 10.18632/oncotarget.17114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosisPMID 28467787Read ↗

Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosisSemantic proximity Read ↗

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic OptionSemantic proximity Read ↗

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosisSemantic proximity Read ↗

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory DiseasesSemantic proximity Read ↗

Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update ReviewSemantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini ReviewSemantic proximity Read ↗

Dextromethorphan inhibits collagen transport in the endoplasmic reticulum eliciting an anti-fibrotic response in <i>ex-vivo</i> and <i>in vitro</i> models of pulmonary fibrosisSemantic proximity Read ↗

[How i treat a patient with idiopathic pulmonary fibrosis].Semantic proximity Read ↗

The role of histone deacetylases in inflammatory respiratory diseases: an updateSemantic proximity Read ↗

Prevention of Drug-Induced Lung Fibrosis via Inhibition of the MRTF/SRF Transcription PathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.